EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

HIV-resistant CD19/HIV-targeted dual CAR T cells control HIV replication and B cell lymphoma concurrently in humanized mice

Nan Liu, David Nardo, Vipin Bhardwaj, Joshua Glover, Divanshu Shukla, James L Riley

Journal of Clinical Investigation · 10.11.2026

DOI: 10.1172/jci211637 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 10.11.2026. Verfasst von Nan Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United Sta…. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Infusion of CD19-directed chimeric antigen receptor (CAR) T cells (CARTs) can result in robust CART expansion, long-term CART persistence, and durable remissions in B cell malignancies. We hypothesized that leveraging this expansion and persistence could enable sustained HIV control by engineering IL-18 secreting CD19 CARTs to co-express an HIV-specific CAR and a signaling-deficient C34-CXCR4 HIV fusion inhibitor (C34-CXCR4*), thereby generating HIV-resistant CD19/HIV dual CARTs. These CD19/HIV dual CARTs functioned as well as single CAR expressing CARTs toward a single target indicating no loss of activity occurred by co-expressing the CARs in the same cell. In a humanized mouse model of leukemia infused with CD4 T cells from a person with HIV (PWH), autologous CD19/HIV dual CARTs achieved tumor eradication comparable to that of CD19-only CARTs, demonstrating preserved antitumor efficacy. Notably, a CD19.BBζ–IL-18 CAR combined with a CD4.28ζ-C34-CXCR4* HIV-specific CAR exhibited enhanced T cell expansion and persistence and superior HIV and tumor control. Together, these findings identify CD19/HIV dual CARTs as a promising strategy to maintain a robust population of HIV-specific CARTs to control viral rebound, while simultaneously treating B cell malignancies, advancing CART based approaches toward durable HIV remission.

Schlagwörter

Stichwörter der Autor:innen

AIDS/HIVHematologyImmunotherapyLeukemiasT cells

Autor:innen und Institutionen

  • Department of Microbiology and Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States of America.

Förderung

  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Liu, N., Nardo, D., Bhardwaj, V., Glover, J., Shukla, D., & Riley, J. L. (2026). HIV-resistant CD19/HIV-targeted dual CAR T cells control HIV replication and B cell lymphoma concurrently in humanized mice. Journal of Clinical Investigation. https://doi.org/10.1172/jci211637

Vancouver

Liu N, Nardo D, Bhardwaj V, Glover J, Shukla D, Riley JL. HIV-resistant CD19/HIV-targeted dual CAR T cells control HIV replication and B cell lymphoma concurrently in humanized mice. Journal of Clinical Investigation. 2026. doi:10.1172/jci211637

BibTeX
@article{Liu2026,
  author = {Liu, Nan and Nardo, David and Bhardwaj, Vipin and Glover, Joshua and Shukla, Divanshu and Riley, James L},
  title = {HIV-resistant CD19/HIV-targeted dual CAR T cells control HIV replication and B cell lymphoma concurrently in humanized mice},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  doi = {10.1172/jci211637}
}
Kostenlos starten →